Type 2 diabetes mellitus patients treated with either the sodium-glucose cotransporter-2 inhibitor empagliflozin or dipeptidyl peptidase 4 inhibitors incur similar overall healthcare costs, according to data from the EMPRISE trial presented at the 79th Scientific Sessions of the American Diabetes Association (ADA 2019).
Supplementation with vitamin D among vitamin D-sufficient adults who are at high risk of developing diabetes does not reduce the risk of developing the disease vs placebo, according to the randomized, placebo-controlled D2d* trial.
Once-weekly subcutaneous injections of dulaglutide in patients with type 2 diabetes (T2D) reduced cardiovascular (CV) events, particularly non-fatal stroke, regardless of their CV history in the longest cardiovascular outcomes trial (CVOT) to date for a GLP-1* receptor agonist, REWIND**. The CV benefits come with potential renal benefits, with the largest effect seen for macroalbuminuria in an exploratory analysis.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.